XIA Chunhua, Ph.D.

Courses Taught:

² Clinical Pharmacology

² Clinical Pharmacokinetics

Research Interests

² Drug Metabolism and Disease Regulation Mechanisms

² Pharmacogenomics, Epigenetics and Clinical Precision Dosing

² Clinical Pharmacokinetics and PK-PD Modeling in New Drug Development

Education and Training

Sep 2006 – Jul 2009| China Pharmaceutical University (Nanjing, China)

Ph.D. in Pharmaceutical Sciences (Major: Pharmacokinetics)

Degree: Doctor of Philosophy (Ph.D.)

Sep 1996 – Jul 1999| Jiangxi University of Traditional Chinese Medicine (Nanchang, China)

Master of Medicine (M.Med.) in Basic Discipline of Integrative Chinese and Western Medicine

Degree: Master of Medicine (M.Med.)

Sep 1991 – Jul 1996| Jiangxi Medical College (Nanchang, China)

Bachelor of Medicine (B.Med.) in Clinical Medicine

Degree: Bachelor of Medicine (B.Med.)

Dec 2013 – Jan 2014| University of Washington Cancer Research Center (USA)

Visiting Scholar

Aug 2010 – Sep 2010| Medpace Clinical Research Center (USA)

Visiting Scholar

Professional Experience

Jul 2015 – Present| School of Pharmacy, Nanchang University (Nanchang, China)

Vice Dean, Professor

Aug 2005 – Jul 2015|School of Pharmacy, Nanchang University (Nanchang, China)

Associate Professor /Professor

Jul 1999 – Jul 2005| Basic Department, Jiangxi Medical College (Nanchang, China)

Teaching Assistant /Lecturer

Professional Appointments and Services

² Expert, National Drug Evaluation Committee

² Expert, National Drug Clinical Trial Institution Qualification Certification and Data Verification

² Vice Chairperson, Committee of Clinical Pharmacology,Chinese Pharmacological Society

² Vice Chairperson and Secretary-General, Committee of Drug Clinical Trials,Chinese Pharmacological Society

² Member, Committee of Drug Metabolism,Chinese Pharmacological Society

² Member, Committee of Analytical Pharmacology, Chinese Pharmacological Society

² Member, Committee of Applied Pharmacology, Chinese Pharmaceutical Association

² Vice Chairman, Jiangxi Provincial Society for Drug Clinical Trials and Research

Honors and Awards

² Second Prize, Teaching Achievement Award of Jiangxi Province (2023)

² National Baosteel Excellent Teacher Award (2021)

² Jiangxi Province "Jinggang Scholar" Award (2020)

² Jiangxi Provincial Government Special Allowance (2018)

² Rank-2 Professor (2017)

² Second Prize, National Science and Technology Progress Award (2016)

² Distinguished Professor of "Nanchang University 215 Talent Project" (2014)

Research Funding Summary

² National-Level Grants: Led 2 sub-projects under the National Mega-Projects for "Major New Drugs Innovation" during the 11th and 12th Five-Year Plan periods, and secured 6 research grants from the National Natural Science Foundation of China (NSFC).

² Major Provincial Grants: Principal Investigator of the Jiangxi Province "Double Thousand Plan" - High-Level Scientific and Technological Innovation Talent Project, and several Key Projects from the Jiangxi Provincial Natural Science Foundation.

² Applied Research: Directed more than 50 industry-sponsored projects on clinical pharmacokinetics and bioequivalence studies for new drug development.

² Educational Reform: Led 4 key projects on educational reform and industry-academia collaboration.

Selected Research Grants (as Principal Investigator)

² Xiong, Y.Q.; Xia, C.H. Construction of a regulatory technology platform for Phase I clinical trial research and risk monitoring. Subproject, National Mega-Project for "Major New Drugs Innovation" (11th Five-Year Plan). No. 2009ZX09309-003-02. ¥2,471,500. 2009.1-2010.12.

² Xiong, Y.Q.; Xia, C.H. Establishment of an internationally standardized technology platform for Phase I clinical trials and data management of innovative drugs. Subproject, National Mega-Project for "Major New Drugs Innovation" (12th Five-Year Plan). No. 2011ZX09302-007-03-2. ¥6,826,000. 2011.1-2013.12.

² Xia, C.H. Mechanism of Shengmai Formula's complex components synergistically against aristolochic acid nephropathy via dual dimensions of PK-PD based on Keap1/Nrf2 and TGF-β/Smad signaling pathways interaction. National Natural Science Foundation of China (NSFC). No. 82560819. ¥320,000. 2026.1-2029.12.

² Xia, C.H. Mechanism of panaxytrol upregulating CYP3A4 expression based on PXR-CAR interaction. National Natural Science Foundation of China (NSFC). No. 82160708. ¥340,000. 2022.1-2025.12.

² Xia, C.H. Pharmacokinetic mechanism of the compatibility theory of "Sovereign, Minister, Assistant" in Shengmai Formula based on the pharmacodynamic material group and the liver-kidney transporter excretion network. National Natural Science Foundation of China (NSFC). No. 81760672. ¥360,000. 2018.1-2021.12.

² Xia, C.H. Drug-drug interaction mechanism of panaxytrol: short-term allosteric effects on the CYP3A4 enzyme binding site and long-term effects on the PXR/CAR regulatory pathway. National Natural Science Foundation of China (NSFC). No. 81560606. ¥516,000. 2016.1-2019.12.

² Xia, C.H. Molecular mechanism of OATPs/Oatps-mediated hepatic transport of ophiopogonin D and its role in the compatibility of Shengmai Formula's complex components. National Natural Science Foundation of China (NSFC). No. 81160411. ¥550,000. 2012.1-2015.12.

² Xia, C.H. Differential effects of Shengmai Formula on various binding sites of the CYP3A4 enzyme and its mechanism. National Natural Science Foundation of China (NSFC). No. 81060275. ¥230,000. 2011.1-2013.12.

² Xia, C. H. Investigating the Mechanism of Shengmai Formula's Multi-Component Synergy against Aristolochic Acid Nephropathy based on a Component-Target-Pathway" Network from the Dual Dimensions of Pharmacokinetics and Pharmacodynamics. Key Project of Natural Science Foundation of Jiangxi Province, ¥200,000, No. 20252BAC250154, 2025.01 - 2028.12, .

² Xia, C.H. Jiangxi Province "Double Thousand Plan" - High-Level Scientific and Technological Innovation Talent. ¥2,000,000. 2021.1-2023.12.

² Xia, C.H. Exploration and Establishment of an International Standard System for Bioequivalence Trial Sample Analysis and Clinical Design. Jiangxi Provincial Key Research and Development Program. ¥200,000. No. 20212BBG73035. 2021.01 - 2023.12.

² Xia, C.H. Multi-dimensional Regulatory Mechanisms of Ursolic Acid/Oleanolic Acid on UGT Target Genes Based on the PKC/NF-κB/PXR Signaling Network and Cross-talk. Jiangxi Provincial Natural Science Foundation Key Project. ¥200,000. No. 20202ACB206013. 2020.01 - 2022.12.

² Xia, C.H. Mechanisms of Panaxytrol's Short-Term Allosteric Effects on CYP3A4 Enzyme and Long-Term Intervention on the PXR Regulatory Pathway. Jiangxi Provincial Natural Science Foundation General Project. ¥50,000. No. 20151BAB205084. 2015.01 - 2017.12.

² Xia, C.H. Jiangxi Province Young Scientist Cultivation Program. Jiangxi Provincial Department of Science and Technology Talent Program. ¥80,000. No. 20133BCB23006. 2013.06 - 2016.06.

Selected Representative Publications (as Corresponding Author)

² Du X, Luo W, Li H, Gu Q, Huang P, Wang C, Li N, Liu F(*), Xia C(*). Hsa_circ_0125356 promotes gemcitabine resistance by modulating WNT canonical and non-canonical pathways via miR-582-5p/FGF9 axis in non-small cell lung cancer. Mol Cancer. 2025 Feb 27;24(1):59.

² Zhu S, Gu Q, Meng C, Liu J, Du X, Liao B, Liu F, Xia C(*). Oleanolic Acid Up-Regulated UGT1A1 and Antagonized Inflammation by Affecting the Binding of PXR and PKCα to HSP90α and SRC1. Phytother Res. 2025 Jul;39(7):3167-3181.

² Huang P, Zhao H, Dai H, Li J, Pan X, Pan W, Xia C(*), Liu F(*). FXR deficiency induced ferroptosis via modulation of the CBP-dependent p53 acetylation to suppress breast cancer growth and metastasis. Cell Death Dis. 2024 Nov 14;15(11):826.

² Lu T, Liao B, Lin R, Meng C, Huang P, Wang C, Liu F(*), Xia C(*). 18β-Glycyrrhetinic acid synergizes with enzalutamide to counteract castration-resistant prostate cancer by inhibiting OATP2B1 uptake of dehydroepiandrosterone sulfate. Eur J Pharmacol. 2024 Nov 15;983:176995.

² Meng C, Zhou L, Huang L, Gu Q, Du X, Wang C, Liu F, Xia C(*). Chlorogenic acid regulates the expression of NPC1L1 and HMGCR through PXR and SREBP2 signaling pathways and their interactions with HSP90 to maintain cholesterol homeostasis. Phytomedicine. 2024 Jan;123:155271.

² Meng C, Zhong L, Lu T, Gu Q, Du X, Liu F, Xia C(*). Complex components of Shengmai formula interact with organic cation transporter 2 (OCT2) in MDCK cells. J Ethnopharmacol. 2023 May 23;308:116278.

² Yan J, Gu Q, Meng C, Liu J, Liu F, Xia C(*). Panaxytriol upregulates CYP3A4 expression through the interaction between nuclear regulators and DNA response elements. J Ethnopharmacol. 2023 Mar 21;310:116398.

² Liu J, Huang C, Liu J, Meng C, Gu Q, Du X, Yan M, Yu Y, Liu F, Xia C(*). Nrf2 and its dependent autophagy activation cooperatively counteract ferroptosis to alleviate acute liver injury. Pharmacol Res. 2023 Jan;187:106563.

² Liu J, Liu J, Meng C, Gu Q, Huang C, Liu F, Xia C(*). NRF2 and FXR dual signaling pathways cooperatively regulate the effects of oleanolic acid on cholestatic liver injury. Phytomedicine. 2023 Jan;108:154529.

² Liu J, Liu J, Meng C, Huang C, Liu F, Xia C(*). Oleanolic acid alleviates ANIT-induced cholestatic liver injury by activating Fxr and Nrf2 pathways to ameliorate disordered bile acids homeostasis. Phytomedicine. 2022 May 14;102:154173.

² Hou J, Zhong L, Liu J, Liu F, Xia C(*). Interaction of the main active components in Shengmai formula mediated by organic anion transporter 1 (OAT1). J Ethnopharmacol. 2022 Jun 28;296:115515.

² Zhang L, Yan J, Liu J, Meng C, Liu F, Xia C(*). Panaxytriol upregulates CYP3A4 expression based on the interaction of PXR, CAR, HSP90α, and RXRα. Phytomedicine. 2022 Apr 6;101:154097.

² Yuan L, Zhang L, Yao N, Wu L, Liu J, Liu F, Zhang H, Hu X, Xiong Y, Xia C(*). Upregulation of UGT1A1 expression by ursolic acid and oleanolic acid via the inhibition of the PKC/NF-κB signaling pathway. Phytomedicine. 2021 Nov;92:153726.

² Wu L, Liu J, Hou J, Zhan T, Yuan L, Liu F, Xiong Y, Hu J, Xia C(*). Interactions of the major effective components in Shengmai formula with breast cancer resistance protein at the cellular and vesicular levels. Biomed Pharmacother. 2021 Jan;133:110939.

² Zhan T, Yao N, Wu L, Lu Y, Liu M, Liu F, Xiong Y, Xia C(*). The major effective components in Shengmai Formula interact with sodium taurocholate co-transporting polypeptide. Phytomedicine. 2019 Jun;59: 152916.

² Yao N, Zeng C, Zhan T, He F, Liu M, Liu F, Zhang H, Xiong Y, Xia C(*). Oleanolic Acid and Ursolic Acid Induce UGT1A1 Expression in HepG2 Cells by Activating PXR Rather Than CAR. Front Pharmacol. 2019 Sep 27; 10:1111.

² Wu J, Yao N, Hu Q, Liu M, Zhang H, Xiong Y, Hu J, Xia C(*). Effect of panaxytriol on cytochrome P450 3A4 via the pregnane X receptor regulatory pathway. Phytother Res. 2019 Apr;33(4):968-975.

² Hu Q, Yao N, Wu J, Liu M, Liu F, Zhang H, Xiong Y, Xia C(*). Constitutive androstane receptor weakens the induction of panaxytriol on CYP3A4 by repressing the activation of pregnane X receptor. Biochem Pharmacol. 2019 Jan;159:32-39.

² Shen Y, Yu Y, Lai W, Li S, Xu Z, Jin J, Yan X, Xing H, Chen X, Xiong A, Xia C(*), He J(*), Hong K. Evaluation of a Potential Clinical Significant Drug-Drug Interaction between Digoxin and Bupropion in Cynomolgus Monkeys. Pharm Res. 2019;36(1):1.

² Chen L, Liu L, Chen Y, Liu M, Xiong Y, Zhang H, Huang S, Xia C(*). Modulation of transporter activity of OATP1B1 and OATP1B3 by the major active components of Radix Ophiopogonis. Xenobiotica. 2019 Oct;49(10):1221-1228.

² Lu Y, Hu Q, Chen L, Zhang H, Huang S, Xiong Y, Xia C(*). Interaction of deoxyschizandrin and schizandrin B with liver uptake transporters OATP1B1 and OATP1B3. Xenobiotica. 2019 Feb;49(2):239-246.

² Liu X, Chen L, Liu M, Zhang H, Huang S, Xiong Y, Xia C(*). Ginsenoside Rb1 and Rd Remarkably Inhibited the Hepatic Uptake of Ophiopogonin D in Shenmai Injection Mediated by OATPs/oatps. Front Pharmacol. 2018 Aug 22;9:957.

² Yang F, Xiong X, Liu Y, Zhang H, Huang S, Xiong Y, Hu X, Xia C(*). CYP2C9 and OATP1B1 genetic polymorphisms affect the metabolism and transport of glimepiride and gliclazide. Sci Rep. 2018 Jul 20;8(1):10994.

² Yang F, Liu L, Chen L, Liu M, Liu F, Xiong Y, Hu X, Xia C(*). OATP1B3 (699G>A) and CYP2C9*2, *3 significantly influenced the transport and metabolism of glibenclamide and glipizide. Sci Rep. 2018 Dec 24;8(1):18063.

² Chen Y, Chen L, Zhang H, Huang S, Xiong Y, Xia C(*). Interaction of sulfonylureas with liver uptake transporters OATP1B1 and OATP1B3. Basic Clin Pharmacol Toxicol. 2018 Aug;123(2):147-154.

Research Awards

² 2016, Second Prize, National Science and Technology Progress Award, Project: Establishment of a New Industrial Preparation System for Rosuvastatin Calcium and Its Formulations and Their Rational Clinical Application(Rank 3/10).

² 2023: Second Prize, Jiangxi Provincial Teaching Achievement Award, Project: Construction and Practice of an Innovative Talent Training System in Pharmacy Featuring Full-Process Integration, Multi-Disciplinary Crossroads, and Industry-Academia-Research Collaboration (Rank 1/15).

² 2023: Third Prize, Jiangxi Medical Science and Technology Award, Project: Mechanisms of Individualized Medication Differences and Drug-Drug Interactions of Statins (Rank 3/6).

² 2014: Third Prize, Jiangxi Provincial Science and Technology Progress Award, Project: Study on Genetic Polymorphisms and Rational Clinical Application of New Statins in Lipid-Regulating Therapy (Rank 2/6).

² 2013: First Prize, Jiangxi Higher Education Institution Scientific and Technological Achievement Award, Project: Molecular Mechanism of OATP1B1 Genetic Polymorphism on Lipid-Lowering Effects of Statins and Their Rational Clinical Application (Rank 2/6).